SEARCH

SEARCH BY CITATION

References

  • 1
    Russo ME. The pathophysiology of epilepsy. Cornell Vet 1981; 71:221247.
  • 2
    Prince D. Neurophysiology of epilepsy. Ann Rev Neurosci 1978; 1:395415.
  • 3
    Delgado-Escueta AV, Ward AA, Woodbury DM. et al. New wave of research in the epilepsies. Adv Neurol 1986; 44:355.
  • 4
    Dichter M., Spencer WA. Penicillin-induced interictal discharge from cat hippo-campus. J Neurophysiol 1969; 32:649662.
  • 5
    Wyler AR, Burchiel KJ, Ward AA. Chronic epileptic foci in monkeys. Epilepsia 1978; 19:475483.
  • 6
    Gastaut H., Fischer-Williams M. The pathophysiology of epileptic seizures. In: FieldJ., ed. Neurophysiology—Handbook of Physiology. Washington : American Physiological Society, 1959:315363.
  • 7
    Morrell F. Physiology and histochemistry of the mirror focus. In: JasperHH, WardAA, PopeA., eds. Basic Mechanisms of the Epilepsies. Boston : Little, Brown, and Co, 1969; 357369.
  • 8
    Goddard CV, Mclntyre DC, Leech CK. A permanent change in brain function resulting from daily electrical stimulation. Exp Neurol 1969; 25:295330.
  • 9
    Morrell F. Human secondary epileptogenic lesions. Neurology 1979; 29:558.
  • 10
    Goldensohn ES. The kindling phenomenon: A reappraisal of its role in human epilepsy (abstr). Washington, DC: Merritt-Putnam Symposium, 1983.
  • 11
    Harris AB, Lockard JS. Absence of seizures or mirror foci in experimental epilepsy after excision of alumina or astrogliotic scar. Epilepsia 1981; 22:107122.
  • 12
    Gloor P., Fariello RG. Generalized epilepsy: Some of its cellular mechanisms differ from those of focal epilepsy. Trends in Neurosciences 1988; 11:6368.
  • 13
    Iadarola MJ, Gale K. Substantia nigra: Site of anticonvulsant activity mediated by γ-aminobutyric acid. Science 1982; 218:12371240.
  • 14
    Loscher W., Schwartz-Porsche D., Frey H-H, et al. Evaluation of epileptic dogs as an animal model of human epilepsy. Arz-neimittel-forschung 1985; 35:8286.
  • 15
    van der Velden NA. Fits in Tervueren shepherd dogs: A presumed hereditary trait. Journal of Small Animal Practice 1968; 9:6370.
  • 16
    Wallace ME. Keeshonds: A genetic study of epilepsy and EEG readings. Journal of Small Animal Practice 1975; 16:110.
  • 17
    Cunningham JG. Canine seizure disorders. J Am Vet Med Assoc 1971; 158:589598.
  • 18
    Bunch SE. Anticonvulsant drug therapy in companion animals. In: KirkRW, ed. Current Veterinary Therapy IX. Philadelphia : WB Saunders, 1986; 836844.
  • 19
    Farnbach GC. Seizures in the dog: Part I. Basis, classification, and predilection. Compendium on Continuing Education for the Practicing Veterinarian 1984; 6:569574.
  • 20
    Bunch SE. Unpublished observations, 1981.
  • 21
    Evans RJ. The nervous system. In: ChandlerEA, GaskellCG, HilberyADR, eds. Feline Medicine and Therapeutics. London : Blackwell Scientific Publications, 1985; 3866.
  • 22
    Schwartze-Porsche D. Feline epilepsy: Current knowledge. Proc Eur Soc Vet Neurol 1987.
  • 23
    Holliday TA. Seizure disorders. Vet Clin North Am 1980; 10:329.
  • 24
    Barker J. The nervous system. In: ChandlerEA, SuttonJB, ThompsonDJ, eds. Canine Medicine and Therapeutics. London : Blackwell Scientific Publications, 1984; 109137.
  • 25
    Cunningham JG, Farnbach GC. Inheritance and idiopathic canine epilepsy. Journal of the American Animal Hospital Association 1988; 24:421424.
  • 26
    Farnbach GC. Serum concentrations and efficacy of phenytoin, phenobarbital and primidone in canine epilepsy. J Am Vet Med Assoc 1984; 184:11171120.
  • 27
    Schwartze-Porsche D., Loscher W., Frey H-H. Therapeutic efficacy of phenobarbital and primidone in canine epilepsy: A comparison. J Vet Pharmacol Ther 1985; 8:113119.
  • 28
    Farnbach GC. Efficacy of primidone in dogs with seizures unresponsive to phenobarbital. J Am Vet Med Assoc 1984; 185:867868.
  • 29
    Kay WJ. Epilepsy in cats. Journal of the American Animal Hospital Association 1975; 11:7782.
  • 30
    Woodbury DM, Kemp JW, Chow SY. Mechanisms of action of antiepileptic drugs. In: WardAA, PenryJK, PurpuraD., eds. Epilepsy. New York : Raven Press, 1983; 179223.
  • 31
    Laird HE. Antiepileptic drug research: An overview. Fed Proc 1985; 44:26272628.
  • 32
    Macdonald RL, McLean MJ, Skerritt JH. Anticonvulsant drug mechanisms of action. Fed Proc 1985; 44:26342639.
  • 33
    McLean MJ, Macdonald RL. Multiple actions of phenytoin on mouse spinal cord neurons in cell culture. J Pharmacol Exp Ther 1983; 227:779789.
  • 34
    McLean MJ, Macdonald RL. Phenytoin and carbamazepine selectively limit sustained high frequency repetitive firing of cultured mouse neurons. Soc Neurosci Abstr 1983; 9:398.
  • 35
    McLean MJ, Taylor CP, Macdonald RL. Phenytoin and carbamazepine limit sustained high frequency repetitive firing of action potentials of hippocampal neurons in cell culture and tissue slices. Soc Neurosci Abstr 1984; 10:873.
  • 36
    Rock DM, McLean MJ, Macdonald RL. Sodium valproate selectively limits sustained high frequency repetitive firing of cultured mouse neurons. Soc Neurosci Abstr 1984; 10:872.
  • 37
    Ramsey RE, Hammond EJ, Perchalski RJ, et al. Brain uptake of phenytoin, phenobarbital, and diazepam. Arch Neurol 1979; 36:535539.
  • 38
    Chapman AG, Meldrum BS. Effects of anticonvulsant drugs on brain amino acid metabolism. In: Epilepsy: An Update on Research and Therapy. New York :Alan Liss, Inc, 1983; 6376.
  • 39
    Loscher W. Comparative study of the inhibition of GABA aminotransferase by different anticonvulsant drugs. Arch Int Pharmacodyn Ther 1980; 243:4855.
  • 40
    Loscher W. Comparative assay of anticonvulsant and toxic potencies of sixteen GABA mimetic drugs. Neuropharmacology 1982; 21:803810.
  • 41
    Loscher W., Frey H-H, Reiche R., et al. High anticonvulsant potency of -aminobutyric acid (GABA)mimetic drug in ger-bils with genetically determined epilepsy. J Pharmacol Exp Ther 1983; 226:839844.
  • 42
    Macdonald RL, Barker JL. Enhancement of GABA-mediated postsynaptic inhibition in cultured mammalian neurons: A common mode of anticonvulsant action. Brain Res 1979; 167:323336.
  • 43
    Shulz DW, Macdonald RL. Barbiturate enhancement of GABA-mediated inhibition and activation of chloride ion conductance: correlation with anticonvulsant and anesthetic action. Brain Res 1981; 209:177188.
  • 44
    Skerritt JH, Rock DM, McLean MJ, et al. Concentration-dependent effects of benzodiazepines on GABA responses and sustained high frequency repetitive firing in mouse cultured neurons. Soc Neurosci Abstr 1984; 10:643.
  • 45
    Bajorek JG, Lee RJ, Lomax P. Neuropeptides: A role as endogenous mediators or modulators of epileptic phenomena. Ann Neurol 1984; 16 (Suppl):3138.
  • 46
    Loscher W. A comparative study of the protein binding of anticonvulsant drugs in serum of dog and man. J Pharmacol Exp Ther 1979; 208:429435.
  • 47
    Loscher W. Kinetics of penetration of common antiepileptic drugs into cerebrospinal fluid. Epilepsia 1984; 25:346352.
  • 48
    Hauptmann A. Luminal bei epilepsie. Munchene Medizinische Wochenschrift 1912; 59:19071909.
  • 49
    Shell L. Antiepileptic drugs. Compend Contin Educ Pract Vet 1984; 6:432440.
  • 50
    Al-Tahan F., Frey H-H. Absorption kinetics and bioavailability of phenobarbital after oral administration to dogs. J Vet Pharmacol Ther 1985; 8:205207.
  • 51
    Ravis WR, Nachreiner RF, Pedersoli WM, et al. Pharmacokinetics of phenobarbital in dogs after multiple oral administration. Am J Vet Res 1984; 45:12831286.
  • 52
    Frey H-H, Loscher W. Pharmacokinetics of anti-epileptic drugs in the dog: A review. J Vet Pharmacol Ther 1985; 8:219233.
  • 53
    Frey H-H. Use of anticonvulsants in small animals. Vet Rec 1986; 118:484486.
  • 54
    Skinner SF, Robertson LT, Artero M., et al. Longitudinal study of phenobarbital in serum, cerebrospinal fluid, and saliva in the dog. Am J Vet Res 1980; 41:600604.
  • 55
    Parker AJ. Treatment of feline and canine seizure disorders. In: KirkRW, ed. Current Veterinary Therapy VII. Philadelphia : WB Saunders, 1980; 830837.
  • 56
    Frey H-H, Goebel W., Loscher W. Pharmacokinetics of primidone and its active metabolites in the dog. Arch Int Pharmacodyn Ther 1979; 242:1430.
  • 57
    Cunningham JC, Haidukewych D., Jensen HA. Therapeutic serum concentrations of primidone and its metabolites, phenobarbital and PEMA in epileptic dogs. J Am Vet Med Assoc 1983; 182:10921094.
  • 58
    Schwartze-Porsche D., Loscher W., Frey H-H. Treatment of canine epilepsy with primidone. J Am Vet Med Assoc 1982; 181:592595.
  • 59
    Goodman LS, Swineyard EA, et al. Anticonvulsant properties of 5-phenyl-5-ethyl hexahydropyrimidine-4,6-dione (MYSOLINE): A new antiepileptic. J Pharmacol Exp Ther 1953; 108:428436.
  • 60
    Sawchuk SA, Parker AJ, Neff-Davis C., et al. Primidone in the cat. Journal of the American Animal Hospital Association 1985; 21:647650.
  • 61
    Arnold K., Gerber N. The rate of decline of diphenylhydantoin in human plasma. Clin Pharmacol Ther 1970; 11:121134.
  • 62
    Maynert EW. The metabolic fate of diphenylhydantoin in the dog, rat, and man. J Pharmacol Exp Ther 1960; 130:275284.
  • 63
    Roye DB, Serrano EE, Hammer RH, et al. Plasma kinetics of diphenylhydantoin in dogs and cats. Am J Vet Res 1973; 34:947950.
  • 64
    Frey H-H, Loscher W. Clinical pharmacokinetics of phenytoin in the dog: A reevaluation. Am J Vet Res 1980; 41:16351638.
  • 65
    Sanders JE, Yeary RA. Serum concentrations of orally administered diphenylhydantoin in dogs. J Am Vet Med Assoc 1978; 172:153156.
  • 66
    Tobin T., Dirdjosudjono S., Baskin SI. Pharmacokinetics and distribution of diphenylhydantoin in kittens. Am J Vet Res 1973; 34:951954.
  • 67
    Sanders JE, Yeary RA, Powers JD, et al. Relationship between serum and brain concentrations of phenytoin in the dog. Am J Vet Res 1979; 40:473476.
  • 68
    Hassell TM, Maguire JH, Cooper CG, et al. Phenytoin metabolism in the cat after long-term oral administration. Epilepsia 1984; 25:556563.
  • 69
    Palm R., Hanstrom L., Hallman SG, et al. The effects of phenytoin on serum and organ concentrations of zinc and copper in cat. Epilepsia 1985; 26:184188.
  • 70
    Pedersoli WM, Redding RW, Nachreiner RF. Blood serum concentrations of orally administered diphenylhydantoin in dogs and pharmacokinetic values after an intravenous injection. Journal of the American Animal Hospital Association 1981; 17:271275.
  • 71
    Loscher W. Plasma levels of valproic acid and its metabolites during continued treatment in dogs. J Vet Pharmacol Ther 1981; 4:111119.
  • 72
    Loscher W., Nau H. Distribution of valproic acid and its metabolites in various brain areas of dogs and rats after acute and prolonged treatment. J Pharmacol Exp Ther 1983; 226:845854.
  • 73
    Frey H-H, Loscher W. Distribution of valproate across the interface between blood and cerebrospinal fluid. Neuropharmacology 1978; 17:637642.
  • 74
    Nafe LA, Parker AJ, Kay WJ. Sodium valproate: A preliminary clinical trial in epileptic dogs. Journal of the American Animal Hospital Association 1981; 17:131133.
  • 75
    Frey H-H, Philippin HP, Scheuler W. Development of tolerance to the anticonvulsant effect of diazepam in dogs. Eur J Pharmacol 1984; 104:2738.
  • 76
    Frey H-H, Philippin H-P, Scherkl R. Development of tolerance to theeffect of benzodiazepines in dogs. In: KoeliaWP, et al., eds. Antiepileptic Drugs. New York : Raven Press, 1986: 7180.
  • 77
    Al-Tahan F., Loscher W., Frey H-H. Pharmacokinetics of clonazepam in the dog. Arch Int Pharmacodyn Ther 1984; 268:180193.
  • 78
    Scherkl R., Scheuler W., Frey H-H. Anticonvulsant effect of clonazepam in the dog: development of tolerance and physical dependence. Arch Int Pharmacodyn Ther 1985; 278:249260.
  • 79
    Dreifuss FE, Penry JK, Rose SW, et al. Serum clonazepam concentrations in children with absence seizures. Neurology 1975; 25:255258.
  • 80
    Browne TR. Clonazepam. N Engl J Med 1978; 299:8126.
  • 81
    Kaplan SA, Alexander K., Jack MJ, et al. Pharmacokinetic profiles of clonazepam in dog and humans and of flunitrazepam in dog. J Pharm Sci 1974; 63:527532.
  • 82
    Farnbach GC. Seizures in the dog: Part II. Compend Contin Educ Pract Vet 1985; 7:505510.
  • 83
    Wilensky AJ, Levy RH, Troupin L., et al. Chlorazepate kinetics in treated epileptics. Clin Pharmacol Ther 1978; 24:22.
  • 84
    Parker AJ. A preliminary report on a new anti-epileptic medication for dogs. Journal of the American Animal Hospital Association 1975; 11:437438.
  • 85
    Schulman J. Epileptic seizures controlled with paramethadione/primidone. Vet Med 1981; 76:827.
  • 86
    Frey H-H, Loscher W. Pharmacokinetics of carbamazepine in the dog. Arch Int Pharmacodyn Ther 1980; 243:180191.
  • 87
    Faigle JW, Brechbuhler S., Felman KF, et al. The biotransformation of carbamazepine. In: BirkmayerW., ed. Epileptic Seizures-Behavior-Pain. Bern : Verlag Hans Huber, 1976; 127140.
  • 88
    Locock C. Discussion of paper by Sieveking EH: Analysis of fifty-two cases of epilepsy observed by the author. Lancet 1857; 1:527528.
  • 89
    Balcar VJ, Erdo SL, Joo F., et al. Neurochemistry of GABAergic system in cerebral cortex chronically exposed to bromide in vivo. J Neurochem 1987; 48:167169.
  • 90
    Woodbury DM, Pippenger CE. Bromides. In: WoodburyDM, PenryJK, PippengerCE, eds. Antiepileptic Drugs. New York : Raven Press, 1982; 791801.
  • 91
    Rauws AG. Pharmacokinetics of bromide ion—an overview. FD Chem Toxic 1983; 21:379382.
  • 92
    Reed DJ, Woodbury DM, Jacobs L., et al. Factors affecting the distribution of iodide in the brain and cerebrospinal fluid. Am J Physiol 1965; 209:757764.
  • 93
    Woodbury DM. Distribution of nonelectrolytes and electrolytes in the brain as affected by alterations in cerebrospinal fluid secretion. Prog Brain Res 1967; 29:297313.
  • 94
    Palmer JW, Clarke HT. Elimination of bromides from the bloodstream. J Biol Chem 1933; 99:435.
  • 95
    Livingston S., Pearson PH. Bromides and the treatment of epilepsy in children. Am J Dis Child 1953; 86:717720.
  • 96
    Goodman L., Gilman A. The Pharmacological Basis of Therapeutics. New York : The Macmillan Co, 1945.
  • 97
    Greensher J., Mofenson HC, Caraccio T. Bromide. In: HaddadL MD, WinchesterJ MD, eds. Clinical Management of Poisoning and Drug Overdose. Philadelphia : WB Saunders Co, 1983; 685686.
  • 98
    Wallace GB, Brodie BB. The distribution of iodide, thiocyanate, bromide, and chloride in the CNS and spinal fluid. J Pharmacol Exp Ther 1939; 65:220226.
  • 99
    Wallace GB, Brodie BB. The passage of bromide, iodide, and thiocyanate into and out of the cerebrospinal fluid. J Pharmacol Exp Ther 1940; 68:5055.
  • 100
    Aminoff MJ, Simon RP. Status epilepticus: causes, clinical features and consequences in 98 patients. Am J Med 1980; 69:657666.
  • 101
    Janz D. Status epilepticus and frontal lobe lesions. J Neurol Sci 1964; 1:446457.
  • 102
    Kreisman NR, Rosenthal M., LaManna JC, et al. Cerebral o.xygenation during recurrent seizures. In: Delgado-EscuetaAV, WasterlainCG, TreimanDM, PorterRJ, eds. Status Epilepticus. New York : Raven Press, 1983; 231239.
  • 103
    Treiman DM, Delgado-Esqueta AV. Complex partial status epilepticus. In: Delgado-EscuetaAV, WasterlainCG, TreimanDM, PorterRJ, eds. Status Epilepticus. New York : Raven Press, 1983:6981.
  • 104
    White PT, Grant P., Mosier J., et al. Changes in cerebral dynamics associated with seizures. Neurology 1961; 11:354362.
  • 105
    Meldrum BS, Horton RW. Physiology of status epilepticus in primates. Arch Neurol 1973; 28:19.
  • 106
    Bleck TP. The pharmacology of tetanus. Clin Neuropharmacol 1986; 9:103120.
  • 107
    Dean JM, Rogers MC. Cerebral vascular disease. Crit Care Clin 1985; 1:327328.
  • 108
    Reempts JV, Borgers M., Belgium B. Ischemic brain injury and cell calcium morphologic and therapeutic aspects. Ann Emerg Med 1985; 14:736741.
  • 109
    Domenighetti GM, Savarry G., Strieker H. Hyperadrenergic syndrome in severe tetanus: Extreme rise in catecholamines responsive to labetolol. Br Med J 1984; 288:14831484.
  • 110
    Granato JE, Stern BJ, Ringel A., et al. Neuroleptic malignant syndrome. Successful treatment with dantrolene and bromo-criptine. Ann Neurol 1983; 14:8990.
  • 111
    White BC, Krause GS, Aust SD, et al. Postischemic tissue injury byiron-mediated free radical lipid peroxidation. Ann Emerg Med 1985; 14:804809.
  • 112
    Waddell WJ, Butler TC. The distribution and excretion of phenobarbital. J Clin Invest 1957; 36:12171226.
  • 113
    Averill DR Jr. Treatment of status epilepticus in dogs with diazepam sodium. J Am Vet Med Assoc 1970; 156:432434.
  • 114
    Klotz U., Antonin K-H, Bieck PR. Pharmacokinetics and plasma binding of diazepam in man, dog, rabbit, guinea pig, and rat. J Pharmacol Exp Ther 1976; 199:6773.
  • 115
    Frey H-H, Loscher W. Anticonvulsant potency of unmetabolised diazepam. Pharmacology 1982; 25:154159.
  • 116
    Loscher W., Frey H-H. Pharmacokinetics of diazepam in the dog. ArchInt Pharmacol 1981; 254:180195.
  • 117
    Winsens M., Jeppsson R., Sjoberg B. Diazepam adsorption to infusion sets and plastic syringes. Acta Anaesthesiol Scand 1981; 25:9396.
  • 118
    Levy RJ, Krall RL. Treatment of status epilepticus with lorazepam. Arch Neurol 1984; 41:605611.
  • 119
    Kaplan SA, Alexander K., Jack ML, et al. Pharmacokinetic profiles of clonazepam in the dog and humans and flunitazepam in the dog. J Pharm Sci 1974; 63:527532.
  • 120
    Bekersky I., Maggio AC, Mattaliano V., et al. Influence of phenobarbital on the disposition of clonazepam and antipyrine in the dog. J Pharmacokinet Biopharm 1977; 5:507512.
  • 121
    Oliver JE. Seizure disorders and narcolepsy. In: OliverJE, HoerleinBF, MayhewIG, eds. Veterinary Neurology. Philadelphia : WB Saunders Co, 1987; 285302.
  • 122
    Macdonald RL, Barker JL. Different actions of anticonvulsants and anesthetic barbiturates revealed by use of cultured mammalian neurons. Science 1978; 200:775777.
  • 123
    Fenner WR. Seizures. In: KornegayJN, ed. Neurologic Disorders. Contemporary Issues in Small Animal Practice. New York : Churchill Livingstone Inc, 1986; 4153.
  • 124
    Crawford TO, Mitchell WG, Fishman LS, et al. Very-high dose phenobarbital for refractory status epilepticus in children. Neurology 1988; 38:10351040.
  • 125
    Bleck TP. Therapy for status epilepticus. Clin Neuropharmacol 1983; 6:255269.
  • 126
    Goldberg MA, Mclntyre HB. Barbiturates in the treatment of status epilepticus. In: Delgado-EsquetaAV, WasterlainCG, TeimanDM, PorterRJ, eds. Status Epilepticus. New York : Raven Press, 1983; 499503.
  • 127
    Partinen M., Kovanen J., Nillson E. Status epilepticus treated by barbiturate anesthesia with continuous monitoring of cerebral function. Br Med J 1981; 282:520521.
  • 128
    Delgado-Escueta AV, Wasterlain C., Treiman DM, et al. Management of status epilepticus. N Engl J Med 1982; 306:13371340.
  • 129
    Demopoulos HB, Flamm E., Seligman M., et al. Molecular pathology of lipids in central nervous system membranes. In: JobosisFE, ed. Oxygen and Physiological Function. Dallas : Professional Information Library, 1976; 491508.
  • 130
    Flamm ES, Seligman ML, Demopoulos HB. Barbiturate protection of the ischemic brain. In: CottrellJ., TurndorfH., eds. Neurosurgical Anesthesia. St. Louis : Mosby, 1980; 248266.
  • 131
    Smith AA. Barbiturate protection in cerebral hypoxia. Anesthesiology 1977; 47:285293.
  • 132
    Miller SM, Cottrell JE, Turndorf H. Cerebral protection by barbiturates and loop diuretics in head trauma: possible modes of action. Bull NY Acad Med 1980; 56:305313.
  • 133
    Weissinger J. Pharmacological principles of drug interactions. Compend Contin Educ Pract Vet 1983; 5:839846.
  • 134
    Delgado-Escueta AV, Enrile-Bascal F. Combination therapy for status epilepticus: Intravenous diazepam and phenytoin. In: Delgado-EsquetaAV, WasterlainCG, TreimanDM, PorterRJ, eds. Status Epilepticus. New York : Raven Press, 1983; 477485.
  • 135
    Janssen PAJ, Niemegeers CJE, Marsboom RPH. Etomidate, a potent non-barbiturate hypnotic: Intravenous etomidate in mice, rats, guinea-pigs, rabbits, and dogs. Arch Int Pharmacodyn Ther 1975; 214:92132.
  • 136
    Wauquier A., Ashton D., van der Starre P. Anticonvulasant profile of etomidate, a non-barbiturate hypnotic. Firenze: Proceedings, 1 lth Epilepsy Int Symp 1979; 135.
  • 137
    Wauquier A., Ashton D., Niemegeers CJE, et al. Etomidate: Antiischemic and anti-anoxic actions in animals. Hamburg: Proceedings, 7th World Congress of Anesthesiologists. 1980; 216.
  • 138
    Doenicke A., Kugler J., Penzel G., et al. Him funkrion und roleranzbreite nach Etomidate, einem neuen barbituratfrer en i.v. applizierbaren hypnoticum. Anaesthesist 1973; 22:357366.
  • 139
    Evans RH, Hill RG. GABA-mimetic action of etomidate. Experientia 1978; 34:13251326.
  • 140
    Wauquier A. Profile of etomidate. Anesthesia 1983; 38:2633.
  • 141
    Renou AM, Vernhiet J., Macrez P., et al. Cerebral blood flow and metabolism during etomidate anesthesia in man. Br J An-aesth 1978; 50:10471051.
  • 142
    Schulte AM, Esch J., Pfiefer G., et al. Der einfluss von etomidate and thiopental auf den gesteigerten intracraniellen druck. Anaesthesist 1978; 27:7175.
  • 143
    Fellows JW, Byrne AJ, Allison SP. Adrenocortical suppression with etomidate. Lancet 1983; 2:54.
  • 144
    Mehta MP, Dillman JB, Sherman BM, et al. Etomidate anesthesia inhibits the cortisol response to surgical stress. Acta An-aesthesiol Scand 1985; 29:486489.
  • 145
    Wagner RL, White PF. Etomidate inhibits adrenocortical function in surgical patients. Anesthesiology 1984; 61:647651.
  • 146
    Wanscher M., Tonnesen E., Huttel M., et al. Etomidate infusion and adrenocortical function. A study in elective surgery. Acta Anaesthesiol Scand 1985; 29:483485.
  • 147
    Duthie DJR, Fraser R., Nimmo WS. Effect of induction of anesthesia with etomidate on corticosteroid synthesis in man. Br J Anaesth 1985; 57:156159.
  • 148
    Fragen RJ, Shanks CA, Molteni A., et al. Effects of etomidate on hormonal responses to surgical stress. Anesthesiology 1984; 61:652656.
  • 149
    Kruse-Elliott KT, Swanson CR, Aucoin DP. Effects of etomidate on adrenocortical function in canine surgical patients. Am J Vet Res 1987; 48:10981100.
  • 150
    Koella WP. Tolerance: Its various forms and their nature. In FreyH-H, FroscherW., KoellaWP, MeinardiH., eds. Tolerance to Beneficial and Adverse Effects of Antiepileptic Drugs. New York : Raven Press, 1986; 16.
  • 151
    Booth NH. Hypnotics, sedatives, and anticonvulsants. In: BoothNH, McDonaldLE, eds. Veterinary Pharmacology and Therapeutics, 5th ed. Ames , IA : Iowa State University Press, 1982; 255266.
  • 152
    Jenkins WL. Drugs acting on the digestive system. In: BoothNH, McDonaldLE, eds. Veterinary Pharmacology and Therapeutics, 5th ed. Ames , IA : Iowa State University Press, 1982; 593606.
  • 153
    Lambie DG, Johnson RH. The effects of phenytoin on phenobarbitone and primidone metabolism. J Neurol Neurosurg Psychiatry 1981; 44:148151.
  • 154
    Balazs T., Farber TK, Feuer G. Drug-induced changes in serum alkaline phosphatase and alanine aminotransferase activities not related to hepatic injuries. Arch Toxicol.: [Suppl], 1978; 1:159163.
  • 155
    Meyer DJ, Noonan NE. Liver tests in dogs receiving anticonvulsant drugs (diphenylhydantoin and primidone). Journal of the American Animal Hospital Association 1981; 17:261264.
  • 156
    Sturtevant F., Hoffman WE, Dorner JL. The effect of three anticonvulsant drugs and ACTH on canine serum alkaline phosphatase. Journal of the American Animal Hospital Association 1977; 13:754757.
  • 157
    Bunch SE, Castleman WL, Baldwin BH, et al. Effects of long-term primidone and phenytoin administration on canine hepatic function and morphology. Am J Vet Res 1985; 46:105115.
  • 158
    Remmer H. Induction of drug metabolizing enzyme system in the liver. Eur J Clin Pharmacol 1972; 5:116136.
  • 159
    Feinman LK, Rubin E., Lieber CS. Adaptation of the liver to drugs. In: OrlandiF., JezequelAM, eds. Liver and Drugs. London : Academic Press, 1972; 4183.
  • 160
    Jezequel AM, Orlandi F. Fine morphology of the human liver as a tool in clinical pharmacology. In: OrlandiF., JezequelAM, eds. Liver and Drugs. London : Academic Press, 1972.
  • 161
    Liechfield MH, Conning DM. Effect of phenobarbitone on plasma andhepatic alkaline phosphatase activity in the dog. Arch Pharmacol 1972; 272:358362.
  • 162
    Vu VT, Bai SA, Abramson FP. Interactions of phenobarbital with propranolol in the dog: 2. Bioavailability, metabolism and pharmacokinetics. J Pharmacol Exp Ther 1983; 224:5561.
  • 163
    Bai SA, Abramson FP. Interaction of phenobarbital with propranolol in the dog: 3. Beta blockade. J Pharmacol Exp Ther 1983; 224:6267.
  • 164
    Gascon-Barre M., Vallieres S., Huet PM. Influence of phenobarbital on the hepatic handling of [3H] vit D in the dog. Am J Physiol 1986; 251:G627G635.
  • 165
    Bunch SE, Baldwin BH, Hornbuckle WE, et al. Compromised hepatic function in dogs treated with anticonvulsant drugs. J Am Vet Med Assoc 1984; 184:444448.
  • 166
    Bunch SE, Castleman WL, Hornbuckle WE, et al. Hepatic cirrhosis associated with long-term anticonvulsant drug therapy in dogs. J Am Vet Med Assoc 1982; 181:357362.
  • 167
    Bunch SE, Conway MB, Center SA, et al. Toxic hepatopathy and intrahepatic cholestasis associated with phenytoin administration in combination with other anticonvulsant drugs in three dogs. J Am Vet Med Assoc 1987; 190:194198.
  • 168
    Rawlins MD. Adverse reactions to drugs. Br Med J 1981; 282:974976.
  • 169
    Booker HE. Idiosyncratic reactions to the antiepileptic drugs. Epilepsia 1975; 16:171181.
  • 170
    Papich MG, Davis LE. Drugs and the liver. Vet Clin North Am 1985; 15:7795.
  • 171
    Poffenbarger EM, Hardy RM. Hepatic cirrhosis associated with long-term primidone therapy in a dog. J Am Vet Med Assoc 1985; 186:978980.
  • 172
    Jennings PB, Utter WF, Friss BL. Effect of long-term primidone treatment in a dog. J Am Vet Med Assoc 1969; 154:393395.
  • 173
    Nash AS. Phenytoin toxicity: A fatal case in a dog with hepatitis and jaundice. Vet Rec 1977; 100:280281.
  • 174
    Babcock JR, Nelson GH. Gingival hyperplasia and dilantin content of saliva: A pilot study. J Am Dent Assoc 1964; 68:195198.
  • 175
    Ishikawa J. Study on hyperplasia of gingiva caused by diphenylhydantoin (II): Experimental study on hyperplasia of gingiva by diphenylhydantoin in cats. Japanese Journal of Conservative Dentistry 1959; 2:169178.
  • 176
    Ishikawa J., Glickman I. Gingival response to the systemic administration of sodium diphenylhydantoin (dilantin) in cats. J Periodontol 1961; 32:149158.
  • 177
    Kutt HL, McDowell F. Intravenous diphenylhydantoin in experimental seizures. Arch Neurol 1968; 18:465471.
  • 178
    Rost DR, Baker R. Gingival hyperplasia induced by sodium diphenylhydantoin in the dog: A case report. Vet Med 1978; 73:585587.
  • 179
    Hendricks PM. Dermatitis associated with the use of primidone in a dog. J Am Vet Med Assoc 1987; 191:237238.
  • 180
    Albright PS, Bruni J. Pharmacokinetic interactions of antiepileptic drugs. J Can Neurol 1984; 11:247251.
  • 181
    Frey H-H, Kampmann E., Nielsen CK. Study on combined treatment with phenobarbital and diphenylhydantoin. Acta Pharmacol Toxicol 1968; 26:284292.
  • 182
    Ciaccio PJ, Duignan DB, Halper JR. Selective inactivation by chloramphenicol of the major phenobarbital-inducible iso-zyme of dog liver cytochrome P-450. Drug Metab Dispos 1987; 15:852856.
  • 183
    Sanders JE, Yeary RA, Fenner WR, et al. Interaction of phenytoin with chloramphenicol or pentobarbital in the dog. J Am Vet Med Assoc 1979; 175:177180.
  • 184
    Adams HR, Isaacson EL, Masters BSS. Inhibition of hepatic microsomal enzymes by chloramphenicol. J Pharmacol Exp Ther 1977; 203:388396.
  • 185
    Campbell CL. Primidone intoxication associated with concurrent use of chloramphenicol. J Am Vet Med Assoc 1983; 182:992994.
  • 186
    Ravis WR, Pedersoli WM, Turco JD. Pharmacokinetics and interactions of digoxin with phenobarbital in dogs. Am J Vet Res 1987; 48:12441249.
  • 187
    Breznock EM. Effects of phenobarbital on digitoxin and digoxin elimination in the dog. Am J Vet Res 1975; 36:371373.
  • 188
    Pedersoli WM, Ganjam VK, Nachreiner RF. Serum digoxin concentrations in dogs before, during, and after concomitant treatment with phenobarbital. Am J Vet Res 1980; 41:16391642.
  • 189
    Solomon GE, Hilgartner MW, Kutt H. Phenobarbital-induced coagulation defects in cats. Neurology 1974; 24:920924.